The present-day problems in tuberculosis control are associated with a difficulty in detecting Mycobacterium tuberculosis (MBT) in due time and in determining its drug sensitivity by conventional microbiological assays. The determination of the drug sensitivity of MBT takes much time from 2 weeks to 3 months, which fails to initiate and perform specific therapy timely. Molecular genetic techniques, including biochip analysis, yield results in 24-48 hours, which solves the problem of choosing and initiating adequate antibacterial therapy in the shortest possible time after tuberculosis is diagnosed. To assess the situation associated with the prevalence of rifampicin-resistant tuberculosis, by using the biochip analysis, the authors have examined 501 patients with tuberculosis who live in the Kyrghyz Republic. Drug resistance has been found in 40.3% of the examinees. At the same time, their primary and secondary drug resistance is 25.7 and 61.8%, respectively. In tuberculosis patients living in Kyrghyzstan, rifampicin resistance of MBT is more frequently due to mutations in 531 (59.2%), 526 (20.8%), and 516 (8.0%) codons in the rpoB gene.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tuberculous meningitis diagnosis and treatment: classic approaches and high-throughput pathways.
Front Immunol
January 2025
Rehabilitation Medicine Department, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University (The First Hospital of Changsha, Changsha, China.
Tuberculous meningitis (TBM), a severe form of non-purulent meningitis caused by (Mtb), is the most critical extrapulmonary tuberculosis (TB) manifestation, with a 30-40% mortality rate despite available treatment. The absence of distinctive clinical symptoms and effective diagnostic tools complicates early detection. Recent advancements in nucleic acid detection, genomics, metabolomics, and proteomics have led to novel diagnostic approaches, improving sensitivity and specificity.
View Article and Find Full Text PDFBackground: Identification of young children with ( )-infection is critical to curb Tuberculosis (TB)-related pediatric morbidity and mortality. The optimal test to identify young children with evidence of -infection remains controversial.
Methods: Using a TB household contact (HHC) study design among 130 Ugandan children less than 5 years with established -exposure, we compared the usefulness of the tuberculin skin test (TST) and QuantiFERON Gold Plus (QFT-Plus) to identify children with evidence for -sensitization.
Although granulomatous interstitial nephritis (GIN) is a rare histological finding in kidney transplants, the joint occurrence of GIN and focal segmental glomerulosclerosis (FSGS) has not, to our knowledge, been reported in the literature. We report a case of GIN and de novo FSGS in kidney transplant recipients leading to allograft failure. A 69-year-old male with a history of end-stage renal disease (ESRD) of unknown etiology, as well as liver failure from hepatitis B and C co-infection, initially had a living unrelated kidney transplant (LURT) in 2007 and subsequently received both liver and kidney transplants (SLKTs) in 2017.
View Article and Find Full Text PDFAdvancing tuberculosis elimination in India: A qualitative review of current strategies and areas for improvement in tuberculosis preventive treatment.
IJID Reg
March 2025
Department of Public Health Science, Indian Institute of Public Health Gandhinagar (IIPHG), Gandhinagar, India.
Tuberculosis (TB), caused by , remains a global health challenge, despite being preventable and curable. The global goal to end TB by 2030, with India targeting a 90% reduction in TB incidence by 2025, demands comprehensive interventions in prevention, early detection, treatment, and capacity building. This study analyzes the 2023 Global TB Reports, published articles, guidelines, and data to explore India's current TB landscape.
View Article and Find Full Text PDFEffect of High-Fat Diets on the Pharmacokinetics of Bedaquiline Fumarate Tablet: A Trial in Healthy Chinese Participants.
Clin Pharmacol Drug Dev
January 2025
Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Bedaquiline is employed to treat multidrug-resistant and extensive drug-resistant tuberculosis by inhibiting the proton pump of adenosine triphosphate synthase in Mycobacterium tuberculosis. This study aims to investigate the effect of high-fat diets on the pharmacokinetics of bedaquiline through a single-center, open-label, randomized trial in healthy Chinese participants. Bedaquiline fumarate tablets were administered at a dosage of 100 mg under both fasted conditions and high-fat diet conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!